KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Share-based Compensation (2018 - 2025)

Vir Biotechnology's Share-based Compensation history spans 8 years, with the latest figure at $11.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 29.26% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $49.1 million, down 37.45%, while the annual FY2025 figure was $49.1 million, 37.45% down from the prior year.
  • Share-based Compensation for Q4 2025 was $11.2 million at Vir Biotechnology, down from $11.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $30.6 million in Q2 2023 and bottomed at $11.2 million in Q4 2025.
  • The 5-year median for Share-based Compensation is $23.4 million (2021), against an average of $21.2 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 421.44% in 2021 before it plummeted 43.97% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $24.4 million in 2021, then grew by 2.03% to $24.9 million in 2022, then rose by 13.7% to $28.3 million in 2023, then plummeted by 43.97% to $15.8 million in 2024, then dropped by 29.26% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Share-based Compensation are $11.2 million (Q4 2025), $11.4 million (Q3 2025), and $12.5 million (Q2 2025).